CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus Novel percutaneous interventional therapies in heart failure with preserved ejection fraction: an integrative review Risk of Mortality Following Catheter Ablation of Atrial Fibrillation How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) Nitrosative stress drives heart failure with preserved ejection fraction Cardiac Resynchronization Therapy and Ventricular Tachyarrhythmia Burden The spectrum of heart failure: value of left ventricular ejection fraction and its moving trajectories Frailty Is Intertwined With Heart Failure: Mechanisms, Prevalence, Prognosis, Assessment, and Management

Review ArticleVolume 74, Issue 5, August 2019

JOURNAL:J Am Coll Cardiol. Article Link

From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5)

DP Leong, JJV McMurray, PG Joseph et al. Keywords: ACE-I; ARB; ARNI; coronary disease; heart failure

ABSTRACT


The pharmacological inhibition of the renin-angiotensin-aldosterone system as a therapeutic strategy is one of the most significant advances in the treatment and prevention of cardiovascular disease in heart failure with reduced ejection fraction and in coronary artery disease. Recently, the addition of neprilysin inhibition to angiotensin receptor blockade has been shown to be even more effective than angiotensin-converting enzyme inhibition alone in heart failure with reduced ejection fraction, marking an important new milestone in heart failure treatment. This review summarizes the major trials that have informed the clinical role of inhibition of the renin-angiotensin-aldosterone and neprilysin pathways, as well as the limitations of these strategies.